Five‐day regimen of azacitidine for lower‐risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single‐arm phase 2 trial

Although azacitidine is the first‐line drug for higher‐risk myelodysplastic syndrome (MDS) patients, its efficacy for lower‐risk MDS remains unestablished. Therefore, we conducted a prospective study to examine the efficacy and safety of a 5‐day regimen of azacitidine (AZA‐5) for lower‐risk MDS. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Morita, Yasuyoshi, Maeda, Yasuhiro, Yamaguchi, Terufumi, Urase, Fumiaki, Kawata, Shuhei, Hanamoto, Hitoshi, Tsubaki, Kazuo, Ishikawa, Jun, Shibayama, Hirohiko, Matsumura, Itaru, Matsuda, Mitsuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172056/
https://www.ncbi.nlm.nih.gov/pubmed/30007103
http://dx.doi.org/10.1111/cas.13739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172056/
https://www.ncbi.nlm.nih.gov/pubmed/30007103
http://dx.doi.org/10.1111/cas.13739

Ejemplares similares